After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the safe route to a public company CEO role, or dive headfirst into the uncertain world of AI in healthcare. The pull toward AI proved irresistible.
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
Related Articles
Anumana Appoints Kevin Ballinger and Jean-Luc Butel to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana Inc., a leader in AI-powered cardiovascular detection algorithms, today announced the appointment of Kevin Ballinger and Jean-Luc Butel to its Board of Directors. In their roles, Ballinger and…January 12, 2026
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…October 05, 2023
StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week
Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation…April 20, 2021
Way of Diagnosing PH in Common Heart Test Gets FDA Support
Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The…May 26, 2022